PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Domperidone - Nausea and vomiting (pregnancy)

PAD Profile : Domperidone - Nausea and vomiting (pregnancy) Important

Keywords :
morning sickness, emesis, anti-emetic
Brand Names Include :
Motilium
Important Information :
Safety alert and cardiac side-effects.

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Oral suspension
  • Tablets
Important Information :
2nd line treatment option but should not be prescribed for longer than 7 days.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
R
SA
Un
Comments :

MHRA drug safety update (December 2019- Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents : https://www.gov.uk/drug-safety-update/domperidone-for-nausea-and-vomiting-lack-of-efficacy-in-children-reminder-of-contraindications-in-adults-and-adolescents

Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 May 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC agreed a traffic light status and place in therapy for drugs used to treat nausea and vomiting in pregnancy.

Visit  the Guideline Profile page for a full list of these drugs and to access the CKS guidelines for nasea & vomiting and pregnancy and the BUMPS website (Best Use of Medicines in Pregnancy).

Associated BNF Codes

04. Central Nervous System
04.06.00. Drugs used in nausea and vertigo
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More